Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Novavax

Pfizer

Coronavirus vaccine stocks Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) were trading notably lower Monday. What Happened: A new review authored by a group of international scientists and published by the Lancet suggeststhat booster doses of the COVID-19 vaccine may not be currently needed for the general population.

Why Moderna, BioNTech, Novavax And Pfizer Are Trading Lower

An article in the Lancet suggested that a booster shot wouldn't be necessary for most people after a review of data from clinical trials, as well as efficacy in the real world.

Moderna Tanks as Review Argues Covid Booster Might Not Be Needed

Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.

Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News

AstraZeneca

Johnson & Johnson

Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.

Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?

Moderna held an R&D day on Thursday during which management highlighted the progress with the COVID-19 vaccine and new development candidates.

Moderna: R&D Day Highlights Impressive Pipeline, COVID-19 Vaccine Revenues Appear Longer-Lasting

Morgan Stanley

Moderna, Inc.'s (MRNA) CEO Stéphane Bancel on Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

Moderna, Inc. (MRNA) Presents at Wells Fargo 2021 Virtual Healthcare Conference (Transcript)

It's been a changing story about the details of the U.S. plan for booster shots.

Will There Be 6-Month or 8-Month COVID Boosters?

Snowflake

These widely owned stocks could be some of the fastest-growing companies on the planet over the next four years.

3 Ultra-Popular Growth Stocks Expected to Increase Sales 559% to 809% by 2024

Moderna Inc. (NASDAQ: MRNA) shares are trading higher Thursday after reports came out the company is going to develop a new vaccine — named mRNA-1073 — which will be a single shot that combines a booster dose of COVID-19 with a booster dose of a flu vaccine. Moderna shares were trading up 7.81% at $455.92 at last check Thursday afternoon.

Could Moderna See Another Leg Up After Breaking Out?

Defiance Nasdaq Junior Biotechnology ETF

Invesco Dynamic Biotechnology & Genome ETF

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that offers protection against both the coronavirus and the seasonal flu. The new vaccine booster, which the biotech company calls mRNA-1073, combines Moderna's current coronavirus vaccine [.

Biotech ETFs Benefit From Moderna Dual Booster Shot News

Moderna (MRNA) is expanding its manufacturing and fill-finish capacities through collaborations deals with multiple companies to support the supply of its COVID-19 vaccine.

Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience

Moderna, Inc. (NASDAQ: MRNA), a biotech that rose to prominence with its successful coronavirus vaccine program, is holding its fifth annual R&D day Thursday. What Happened: At the event, Cambridge, Massachusetts-based Moderna detailed recent progress in its clinical programs and issued updates on new development candidates.

Moderna Shares Gain Amid R&D Day Presentations: What You Need To Know

Moderna is developing a single dose vaccine that combines the company's Covid vaccine and a flu booster.

Moderna says it's developing a single vaccine for Covid and flu boosters - shares gain

Moderna Inc. MRNA, -3.09% said Thursday it had a cash position of about $15 billion as of Aug. 31. The company made the disclosure as it offered an update on its line of product candidates based on mRNA technology, that includes a vaccine against COVID-19, the first Moderna product to win authorization from the U.S. Food and Drug Administration.

Moderna says it has about $15 billion in cash, working on combined COVID/seasonal flu booster

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces significant advances across industry-leading mRNA portfolio at 2021 R&D Day.

Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day

U.S. health officials reportedly have questions about the biotech's booster data.

Why Moderna Boosters May Not Be Available as Soon as Pfizer-BioNTech Boosters

PayPal

Invesco QQQ

U.S. indices were trading lower Wednesday as stocks pull back following August strength. Investors continue to watch for signs of a Fed taper and weigh the COVID-19 Delta variant's impact on the economy.

Moderna And PayPal Lead The QQQ Lower

Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.

Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy

Moderna stock (NASDAQ: MRNA) has rallied by about 13% over the last week (five trading days) and currently trades at about $417 per share. In contrast, the S&P 500 is up by just about 0.5% over the same period.

Moderna Stock Gains On More Good News, But Is It A Buy?

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Biomanufacturing--Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine

Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine

Researchers have been comparing the two vaccines in various studies.

Moderna Beats Pfizer by This 1 Measure. Here's Why Pfizer Investors Shouldn't Worry.

Apple

Markets were mostly lower, but good news helped lift some big names.

These 2 Stocks Made Monster Moves Tuesday

Shares of Moderna Inc. rallied toward a fifth straight gain Tuesday, after Morgan Stanley analyst Matthew Harrison added nearly $150 to his price target on an increased outlook for the biotechnology company's COVID-19 vaccine sales.

The Ratings Game: Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley

Recent announcements and a pair of analyst price target hikes have put some zip into the company's stock price.

News for Moderna Stock (MRNA)